By Fineline Cube 
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official commencement of construction for its new microbial commercial production base in Wenjiang District, Chengdu. This strategic expansion underscores WuXi Biologics’ commitment to enhancing its microbial therapy production capabilities.
Facility Details
The facility will be equipped with 15,000L fermenters in its first phase and will have an annual output capacity of 80-110 batches. It is designed to be scalable up to a 60,000L maximum fermentation capacity. The base will feature China’s first dual-chamber lyophilized formulation line and a vial filling line capable of producing over 10 million doses per year.
Technological Advancements
The production base will utilize WuXi Biologics’ microbial expression platform EffiX, which is optimized for high-yield, high-quality, and scalable production of innovative biologics. This platform will play a crucial role in meeting the growing demand for advanced biologic therapies.
Collaborations
WuXi Biologics has established collaborations with VISEN Pharmaceuticals and Virogen Biotechnology. VISEN’s lonapegsomatropin, a long-acting growth hormone for pediatric growth hormone deficiency (PGHD), will be produced at the new site, leveraging the base’s advanced production capabilities.-Fineline Info & Tech